Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, Rockville, MD, USA.
Hospital Clínic i Provincial de Barcelona, CDB, ISGlobal, Barcelona, Universitat de Barcelona, Barcelona, Spain.
Malar J. 2018 Oct 22;17(1):378. doi: 10.1186/s12936-018-2533-9.
This opinion article deals with the diagnostic clinical challenges faced by clinicians or health care workers in malaria-endemic areas when a severely sick child presents to the clinic with fever, coma or respiratory distress. Indeed, the coexistence of malaria with other severe infections like meningitis, invasive bacterial infection or pneumonia makes appropriate treatment allocation a matter of life and death. The use of biomarkers has been proposed as a potential solution to this problem. The arrival of high-throughput technologies allowed thousands of molecules (transcripts, proteins and metabolites) to be been screened in clinical samples from large cohorts of well/characterised patients. The major aim of these studies was to identify biomarkers that inform important decisions: should this child be referred to hospital? Should antibiotics, anti-malarials, or both, be administered? There is a large discrepancy between the number of biomarker discovery studies published and the number of biomarkers that have been clinically validated, let alone implemented. This article reflects on the many opportunities and obstacles encountered in biomarker research in malaria-endemic areas.
这篇观点文章探讨了疟疾流行地区的临床医生或医护人员在面对重病儿童出现发热、昏迷或呼吸窘迫等症状时所面临的诊断临床挑战。事实上,疟疾与其他严重感染(如脑膜炎、侵袭性细菌感染或肺炎)同时存在,使得正确的治疗分配成为生死攸关的问题。生物标志物的应用被认为是解决这一问题的潜在方法。高通量技术的出现使得能够在大量经过充分特征描述的患者的临床样本中筛选数千种分子(转录本、蛋白质和代谢物)。这些研究的主要目的是确定能够提供重要决策信息的生物标志物:是否需要将孩子转至医院?是否应该给予抗生素、抗疟药或两者都用?已发表的生物标志物发现研究数量与经过临床验证的生物标志物数量之间存在很大差距,更不用说实施了。本文就疟疾流行地区生物标志物研究中遇到的诸多机遇和障碍进行了反思。